A Phase I/II Study of the Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors

Trial Profile

A Phase I/II Study of the Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs Mogamulizumab (Primary)
  • Indications Adenocarcinoma; Breast cancer; Gastric cancer; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Sep 2017 Planned End Date changed from 1 Oct 2017 to 1 Oct 2018.
    • 05 Sep 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.
    • 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top